AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/amiloride
Number of subjects: 5669
Study 10818061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5669
Study 10818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line drugs (Atenolol or Enalapril)
Number of subjects: 5669
Study 10818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension treatment
Number of subjects: 5669
Study 8641121 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid
Number of subjects: 44
Study 8641121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 1522663 — intervention group
Group type: EXPERIMENTAL
Intervention: Single prophylactic injection of gentamicin
Number of subjects: 100
Study 1522663 — intervention group
Group type: COMPARATOR
Intervention: Five days course of gentamicin
Number of subjects: 100
Study 6404121 — intervention group
Group type: EXPERIMENTAL
Intervention: Disoprofol with fentanyl
Number of subjects: 60
Study 6404121 — intervention group
Group type: EXPERIMENTAL
Intervention: Disoprofol with alfentanil
Number of subjects: 60
Study 6404121 — intervention group
Group type: EXPERIMENTAL
Intervention: Disoprofol with midazolam
Number of subjects: 60
Study 6404121 — intervention group
Group type: EXPERIMENTAL
Intervention: Disoprofol without premedication
Number of subjects: 60
Study 30391169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 900
Study 30391169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 900
Study 30391169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 29846435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) program, conducted three times a week for 16 weeks at an intensity equivalent to 70-110% of ventilatory anaerobic threshold (VAT).
Number of subjects: 66
Study 29846435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) program, conducted three times a week for 16 weeks.
Number of subjects: 66
Study 29846435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 66
Study 27809925 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention delivered over the telephone for common mental health disorders, 10 sessions
Number of subjects: 18
Study 27809925 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (12-week waiting period)
Number of subjects: 18
Study 25312396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (BIBF 1120) at a dose of 200mg twice daily
Number of subjects: 32
Study 25312396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (BIBF 1120)
Number of subjects: 32
Study 22924178 — intervention group
Group type: EXPERIMENTAL
Intervention: Free air carbon dioxide enrichment (550 ppm)
Number of subjects: 0
Study 22924178 — intervention group
Group type: COMPARATOR
Intervention: Drought (precipitation exclusion)
Number of subjects: 0
Study 22924178 — intervention group
Group type: COMPARATOR
Intervention: Temperate climate (THI 57‐63)
Number of subjects: 0
Study 22924178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild heat (THI 68‐71)
Number of subjects: 0
Study 22924178 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe heat (THI 75‐80)
Number of subjects: 0
Study 20970572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/d paricalcitol (n=25)
Number of subjects: 42
Study 20970572 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 42
Study 18039918 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01% gel applied two times per week for 3 weeks
Number of subjects: 82
Study 18039918 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 82
Study 16135920 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy by inexperienced surgeons aged 45 years or older
Number of subjects: 1629
Study 16135920 — intervention group
Group type: EXPERIMENTAL
Intervention: Open herniorrhaphy
Number of subjects: 1629
Study 12021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine or 6-mercaptopurine
Number of subjects: 122
Study 12021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant methotrexate
Number of subjects: 122
Study 12021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TPMT activity in adult patients with inflammatory bowel disease
Number of subjects: 122
Study 12021625 — intervention group
Group type: EXPERIMENTAL
Intervention: TPMT activity
Number of subjects: 122
Study 12021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrations of methylthioinosine monophosphate or thioguanine nucleotides
Number of subjects: 122
Study 12021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurine metabolism
Number of subjects: 122
Study 10071518 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 15
Study 10071518 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 15
Study 10071518 — intervention group
Group type: EXPERIMENTAL
Intervention: diphenhydramine 50 mg
Number of subjects: 15
Study 10071518 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine 8 mg
Number of subjects: 15
Study 10071518 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 10071518 — intervention group
Group type: EXPERIMENTAL
Intervention: All H1-receptor antagonists
Number of subjects: 15
Study 7740062 — intervention group
Group type: EXPERIMENTAL
Intervention: ultralow tar/nicotine (tn) cigarettes
Number of subjects: 12
Study 7740062 — intervention group
Group type: EXPERIMENTAL
Intervention: TN and tn cigarettes
Number of subjects: 12
Study 7740062 — intervention group
Group type: EXPERIMENTAL
Intervention: TN, tn, and Tn cigarettes
Number of subjects: 12
Study 7740062 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking of olfactory cues
Number of subjects: 12
Study 7740062 — intervention group
Group type: EXPERIMENTAL
Intervention: tn cigarettes
Number of subjects: 12
Study 7740062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tn cigarettes
Number of subjects: 12
Study 1705193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined contraceptive pills containing desogestrel and gestodene
Number of subjects: 40
Study 1705193 — intervention group
Group type: COMPARATOR
Intervention: Control values (not specified)
Number of subjects: 40
Study 6789354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 24
Study 6789354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 26 mg
Number of subjects: 24
Study 6789354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 45 mg
Number of subjects: 24
Study 6789354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6789354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (all doses)
Number of subjects: 24
Study 31844458 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course on antimicrobial resistance (AMR)
Number of subjects: 64
Study 31844458 — intervention group
Group type: COMPARATOR
Intervention: Control group online course about microorganisms in dentistry
Number of subjects: 64
Study 28714526 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning 4 cycles of 30 s inflation and 30 s deflation (PC-1)
Number of subjects: 74
Study 28714526 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning 4 cycles of 60 s (PC-2)
Number of subjects: 74
Study 28714526 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (PC-1 and PC-2 combined)
Number of subjects: 74
Study 28714526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 25622803 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants placed with osteotome sinus floor elevation (OSFE) without grafting (test group)
Number of subjects: 37
Study 25622803 — intervention group
Group type: COMPARATOR
Intervention: Short implants placed with osteotome sinus floor elevation (OSFE) with grafting (control group)
Number of subjects: 37
Study 23265387 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (15D)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: COMPARATOR
Intervention: Control arm (15D)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (EQ-5D)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: COMPARATOR
Intervention: Control arm (EQ-5D)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SF-6D)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: COMPARATOR
Intervention: Control arm (SF-6D)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (15D, subsample)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: COMPARATOR
Intervention: Control arm (15D, subsample)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (EQ-5D, subsample)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: COMPARATOR
Intervention: Control arm (EQ-5D, subsample)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SF-6D, subsample)
Number of subjects: 7011
Study 23265387 — intervention group
Group type: COMPARATOR
Intervention: Control arm (SF-6D, subsample)
Number of subjects: 7011
Study 21958927 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q LMA
Number of subjects: 24
Study 21958927 — intervention group
Group type: COMPARATOR
Intervention: Soft Seal LMA
Number of subjects: 24
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive gay
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gay with some bisexuality
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gay with mixed sexual history
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisexual
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual with male-to-male sex
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and social characteristics
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity and partnerships
Number of subjects: 2932
Study 20390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of discrimination and PLWHA activities
Number of subjects: 2932
Study 17634459 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks through week 24
Number of subjects: 668
Study 17634459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 15618252 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg rLH
Number of subjects: 153
Study 15618252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 15618252 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg rLH
Number of subjects: 153
Study 11973100 — intervention group
Group type: EXPERIMENTAL
Intervention: Carticaine 4% adrenaline hyaluronidase mixture
Number of subjects: 200
Study 11973100 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% adrenaline hyaluronidase mixture
Number of subjects: 200
Study 9787958 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 16
Study 9787958 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 16
Study 7543701 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0
Study 2774785 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician audit with periodic feedback
Number of subjects: 0
Study 2774785 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit‐based strategy directed at both patient and physician
Number of subjects: 0
Study 2774785 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control arm)
Number of subjects: 0
Study 215096 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 215096 — intervention group
Group type: COMPARATOR
Intervention: Morphine (120 mg doses)
Number of subjects: 0
Study 31077671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen patch
Number of subjects: 40
Study 31077671 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac patch
Number of subjects: 40
Study 28975998 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 16
Study 26341987 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 80 mg orally twice daily for 28 days
Number of subjects: 52
Study 26341987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23561868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (twice a week for one year)
Number of subjects: 70
Study 23561868 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (thoracic extension exercises)
Number of subjects: 70
Study 23561868 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Pilates and home exercise groups
Number of subjects: 70
Study 22169631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet-based intervention for smoking cessation
Number of subjects: 2298
Study 22169631 — intervention group
Group type: COMPARATOR
Intervention: Nontailored Internet-based intervention for smoking cessation (Control)
Number of subjects: 2298
Study 19209172 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 111
Study 19209172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 16719722 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (viewed 3 ads challenging normative beliefs about marijuana use)
Number of subjects: 435
Study 16719722 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not explicitly mentioned in the abstract)
Number of subjects: 435
Study 14734920 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection rate of 0.5 mL/s
Number of subjects: 60
Study 14734920 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection volume (2, 10, 20 mL)
Number of subjects: 60
Study 14734920 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rates of 1 to 2 mL/s with a minimum of 20 mL gadolinium dimeglumine
Number of subjects: 60
Study 11743482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate/61% ethanol antiseptic hand preparation
Number of subjects: 58
Study 11743482 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate antimicrobial product (control)
Number of subjects: 58
Study 10638893 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.2 mg/kg)
Number of subjects: 30
Study 10638893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg)
Number of subjects: 30
Study 9162612 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum bread (7.6 g guar per meal)
Number of subjects: 14
Study 9162612 — intervention group
Group type: COMPARATOR
Intervention: Control (75 g carbohydrate breakfast meals of control bread)
Number of subjects: 14
Study 1513939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradural anesthesia with 26G needle, puncture directed parallel to dura mater fibers (group 1)
Number of subjects: 270
Study 1513939 — intervention group
Group type: COMPARATOR
Intervention: Intradural anesthesia with 26G needle, puncture directed perpendicular to dura mater fibers (group 2)
Number of subjects: 270
Study 6839561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizolemide (50 mg i.v.)
Number of subjects: 15
Study 6839561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6839561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizolemide
Number of subjects: 15
Study 31347916 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge/tools and solutions for improving experimental design
Number of subjects: 16
Study 30120138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg
Number of subjects: 570
Study 30120138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg
Number of subjects: 570
Study 30120138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 900 mg
Number of subjects: 570
Study 30120138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 27614276 — intervention group
Group type: EXPERIMENTAL
Intervention: Equestrian therapy (24 biweekly sessions over 3 months)
Number of subjects: 14
Study 27614276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 24132052 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy (MMT)
Number of subjects: 30
Study 24132052 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 22192423 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose picosulfate, magnesium oxide, and citric acid solution (1 sachet at 7:00 pm and another sachet 4 hours before colonoscopy)
Number of subjects: 236
Study 22192423 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing regimen (1 sachet at 5:00 pm and 10:00 pm the night before colonoscopy)
Number of subjects: 236
Study 21056283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-free diet for 2 weeks
Number of subjects: 13
Study 21056283 — intervention group
Group type: COMPARATOR
Intervention: Baseline d-IBS patients
Number of subjects: 13
Study 17592349 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 3 mg/kg
Number of subjects: 41
Study 17592349 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg/kg
Number of subjects: 41
Study 16298774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 31
Study 16298774 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 31
Study 12467851 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric method of estimating Doppler ultrasound umbilical maximal flow waveform envelope; No specific dosage or duration mentioned.
Number of subjects: 327
Study 12467851 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of the estimation procedure; No specific dosage or duration mentioned.
Number of subjects: 327
Study 9822227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 91
Study 9822227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 91
Study 7644550 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular array of six coloured circles (condition i)
Number of subjects: 0
Study 7644550 — intervention group
Group type: EXPERIMENTAL
Intervention: Equiluminant grey circles (condition ii)
Number of subjects: 0
Study 7644550 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular array with clockwise shift (condition iii)
Number of subjects: 0
Study 2497490 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 10
Study 2497490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30788839 — intervention group
Group type: EXPERIMENTAL
Intervention: New-design audit and feedback (NA&F)
Number of subjects: 0
Study 30788839 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational material (PEM)
Number of subjects: 0
Study 30788839 — intervention group
Group type: COMPARATOR
Intervention: Routinely conducted audit and feedback (RA&F)
Number of subjects: 0
Study 30788839 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prescribing of injectables
Number of subjects: 0
Study 27899497 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 351
Study 27899497 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 351
Study 27899497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 27899497 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 351
Study 26302276 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 300
Study 26302276 — intervention group
Group type: COMPARATOR
Intervention: Control (brochure) group
Number of subjects: 300
Study 23263559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus once-daily regimen
Number of subjects: 219
Study 23263559 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus twice-daily regimen
Number of subjects: 219
Study 21719530 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin embedded in a phosphorylcholine matrix (XPC group)
Number of subjects: 30
Study 21719530 — intervention group
Group type: COMPARATOR
Intervention: Phosphorylcholine coating (PC group)
Number of subjects: 30
Study 19127975 — intervention group
Group type: EXPERIMENTAL
Intervention: Free primary health care (prepayment scheme allowing free primary care including drugs)
Number of subjects: 2592
Study 19127975 — intervention group
Group type: COMPARATOR
Intervention: User fees for health care (control group)
Number of subjects: 2592
Study 19127975 — intervention group
Group type: EXPERIMENTAL
Intervention: Free primary health care (prepayment scheme)
Number of subjects: 2592
Study 16639496 — intervention group
Group type: EXPERIMENTAL
Intervention: MR fluoroscopy
Number of subjects: 28
Study 16639496 — intervention group
Group type: COMPARATOR
Intervention: Manometry
Number of subjects: 28
Study 16639496 — intervention group
Group type: COMPARATOR
Intervention: Barium contrast radiography
Number of subjects: 28
Study 14752429 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (left internal thoracic artery on left anterior descending coronary artery plus radial artery)
Number of subjects: 160
Study 14752429 — intervention group
Group type: COMPARATOR
Intervention: Standard coronary artery bypass graft surgery (left internal thoracic artery on left anterior descending coronary artery plus saphenous veins)
Number of subjects: 160
Study 11423055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.015 microg/kg/min)
Number of subjects: 305
Study 11423055 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (standard therapy)
Number of subjects: 305